Table 1.
Drugs targeting CD47-SIRPα axis that are currently being tested in humans.
| Drug name | Company | Mechanism of action | Clinical trial ID | Target malignancy | Combined with | Clinical phase | Status (June 2020) |
|---|---|---|---|---|---|---|---|
| Magrolimab (Hu5F-G4) | Gilead Sciences (previously, Forty-Seven Inc.) | Anti-CD47 mAb | NCT02953509 | Relapsing NHL | Rituximab | Phase 1 & 2 | Recruiting |
| NCT03869190 | Urothelial carcinoma | Several | Phase 1 & 2 | Recruiting | |||
| NCT03248479 | AML & MDS | Azacitidine | Phase 1 | Recruiting | |||
|
| |||||||
| BI735063 | OSE Immunotherapeutics/Boehringer Ingelheim | Anti-SIRPα mAb | NCT03990233 | Advanced solid tumors | Monotherapy or PD-1 inhibitor (BI 754091) | Phase 1 | Recruiting |
|
| |||||||
| CC95251 | Celgene | Anti- SIRPα mAb | NCT03783403 | Advanced solid & hematologic cancers | Rituximab or Cetuximab | Phase 1 | Recruiting |
|
| |||||||
| IBI188 | Innovent Biologics (Suzhou) Co. Ltd. | Anti-CD47 mAb | NCT03763149 | Advanced malignant tumors and lymphomas | Monotherapy | Phase 1 | Recruiting |
| NCT03717103 | Advanced malignancies | Rituximab | Phase 1 | Recruiting | |||
|
| |||||||
| TTI621 | Trillium Therapeutics Inc. | SIRPαFc-soluble recombinant fusion protein | NCT02663518 | Hematologic malignancies and selected solid tumors | Rituximab or Nivolumab | Phase 1 | Recruiting |
|
| |||||||
| TT622 | Trillium Therapeutics Inc. | SIRPα-IgG4 Fc-soluble recombinant fusion protein | NCT03530683 | Refractory lymphoma and myeloma | Monotherapy, rituximab, PD-1 inhibitor, or proteasome inhibitor | Phase 1 | Recruiting |
|
| |||||||
| AO176 | Arch Oncology | Anti-CD47 mAb | NCT03834948 | Multiple solid malignancies | Monotherapy | Phase 1 | Recruiting |
|
| |||||||
| ALX148 | ALX Oncology Inc. | SIRPα soluble recombinant fusion protein | NCT03013218 | Advanced Solid & Hematologic Cancers | Monotherapy, Pembrolizumab, Trastuzumab, rituximab, Ramucirumab+ Paclitaxel, 5-FU+ Cisplatin | Phase 1 | Recruiting |